L26/O-141 Intraovarian platelet-rich plasma does not improve embryo quality or ovarian response in women with diminished ovarian reserve: a randomised controlled trial
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.141 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von D.H. Barad und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does intraovarian platelet-rich plasma (PRP) improve embryo quality, ovarian biomarkers, or pregnancy outcomes compared with platelet-poor plasma (PPP) in women with diminished ovarian reserve (DOR)? Summary answer PRP did not improve embryo quality, ovarian response, hormone markers, or pregnancy outcomes compared with PPP. What is known already Autologous PRP has been promoted as a potential strategy to improve ovarian function and fertility in women with DOR, based largely on uncontrolled case series and biologic plausibility related to growth factors release. Reported improvements in hormone levels, follicular development, and oocyte yield remain inconsistent, and few randomized controlled data exist. Additionally, the absence of appropriate control groups and standardized preparation protocols limits interpretation of published studies and has contributed to wide clinical adoption despite limited evidence. Study design, size, duration Randomized, quadruple-blinded, placebo-controlled trial with planned enrollment of 90 participants; 68 randomized to date; 65 initiated a post-randomization IVF attempt. Recruitment began February 2020 and was halted following an interim analysis indicating a low likelihood of treatment benefit. Participants/materials, setting, methods Women aged ≤44 years with DOR (FSH >12 IU/L, AMH <1.0 ng/mL, and <6 oocytes in a prior cycle) were randomized to intraovarian PRP or PPP prepared using RegenLab centrifugation. Primary endpoint was ≥1 day-3 eight-cell embryo with <5% fragmentation obtained from the first IVF cycle. Cancelled cycles due to lack of response were analyzed as failures; true dropouts were excluded. Hormone levels and pregnancy outcomes were assessed exploratorily. Trial registration number ClinicalTrials.gov identifier: NCT04278313 Main results and the role of chance Sixty-five participants initiated post-randomization IVF (PRP n = 32; PPP n = 33); 14 cycles were cancelled (failed); 52 completed cycles were evaluable for embryo quality (PRP n = 26; PPP n = 26). No PRP participant achieved the primary endpoint of ≥ 1 high-quality day-3 embryo, compared with one participant in the PPP arm (0/26 vs 1/26; Fisher’s exact p = 1.00). A sensitivity analysis incorporating day-4 embryos yielded identical results. Median usable embryo yield was numerically similar or slightly higher in PPP than PRP (median 9 vs 5 embryos), with no difference in the proportion achieving any usable embryo (81% PRP vs 76% PPP; p = 0.77). Baseline and post-treatment AMH, FSH, and estradiol did not differ between groups. No signal favoring PRP was observed for clinical pregnancy or live birth. Overall, effect estimates showed no evidence of efficacy or biological effect for PRP, with observed differences consistent with random variation. Limitations, reasons for caution The primary endpoint was rare in this severe DOR population, limiting power to detect small effects. Some hormone data were incomplete, and long-term reproductive outcomes remain limited by sample size. Wider implications of the findings These findings do not support routine clinical use of intraovarian PRP for DOR. Rigorous randomized data suggest limited biological efficacy, emphasizing the need for caution before adopting costly or invasive ovarian “rejuvenation” interventions. Trial registration number Yes
Zitieren
APA
Barad, D., Gayete-Lafuente, S., Guijarro-Baude, L., & Gleicher, N. (2026). L26/O-141 Intraovarian platelet-rich plasma does not improve embryo quality or ovarian response in women with diminished ovarian reserve: a randomised controlled trial. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.141
Vancouver
Barad D, Gayete-Lafuente S, Guijarro-Baude L, Gleicher N. L26/O-141 Intraovarian platelet-rich plasma does not improve embryo quality or ovarian response in women with diminished ovarian reserve: a randomised controlled trial. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.141
BibTeX
@article{Barad2026,
author = {Barad, D.H. and Gayete-Lafuente, S. and Guijarro-Baude, L. and Gleicher, N.},
title = {L26/O-141 Intraovarian platelet-rich plasma does not improve embryo quality or ovarian response in women with diminished ovarian reserve: a randomised controlled trial},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.141}
}
EUVIMED